Arcus Biosciences (NYSE:RCUS) President Sells $383,993.61 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 19,019 shares of the firm’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $20.19, for a total value of $383,993.61. Following the sale, the president directly owned 1,169,214 shares in the company, valued at $23,606,430.66. The trade was a 1.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $19.70 on Friday. The company has a market capitalization of $2.13 billion, a PE ratio of -5.73 and a beta of 0.77. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $22.11. The company has a current ratio of 3.65, a quick ratio of 4.50 and a debt-to-equity ratio of 0.22. The stock’s fifty day simple moving average is $13.95 and its 200 day simple moving average is $10.75.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.06. The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The firm’s revenue was down 45.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.00) EPS. On average, research analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on RCUS. Citigroup raised their price objective on Arcus Biosciences from $54.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday, October 8th. HC Wainwright raised their price objective on Arcus Biosciences from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday. The Goldman Sachs Group raised their price objective on Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Wells Fargo & Company lifted their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.44.

Institutional Trading of Arcus Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of RCUS. Woodline Partners LP raised its stake in shares of Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after purchasing an additional 1,603,367 shares during the period. Gilead Sciences Inc. increased its position in shares of Arcus Biosciences by 4.5% in the first quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company’s stock valued at $246,684,000 after acquiring an additional 1,363,636 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Arcus Biosciences by 24.1% in the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after acquiring an additional 1,298,584 shares during the last quarter. RA Capital Management L.P. acquired a new stake in shares of Arcus Biosciences in the first quarter valued at about $8,920,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Arcus Biosciences in the first quarter valued at about $8,500,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.